Skip to main content

Newsletter block in header

prev
next

Languages

You are here

Neglected Diseases 

Neglected diseases often affect people living in developing countries. As a result, pharmaceutical companies have little interest in working to find a cure for these diseases.  Stimulating awareness about the urgent need for new, better treatment and tests for diseases like leishmaniasis, sleeping sickness and Chagas  disease  is key to the work of MSF’s Access Campaign and the Drugs for Neglected Diseases Initiative (DNDi) of which MSF was a founding partner.

2018 MSF team examines a snakebite wound on a patient’s foot in Abdurafi, Ethiopia.
28/01/2021

No more neglected diseases, no more neglected patients

Patients with neglected tropical diseases (NTDs) need better access to diagnosis and to treatment that is safe and effective

Embedded thumbnail for Facing Noma
19/11/2019

Facing Noma

Noma is a little understood, rapidly progressing gangrenous infection of the mouth and face, associated with a high mortality rate. This preventable disease eats away rapidly tissue, leaving survivors with holes and facial disfigurements that cause them life-threatening impairments and provokes a social stigma.
Embedded thumbnail for Snakebite | Affordable treatment needed, now
24/05/2019

Snakebite | Affordable treatment needed, now

In Agok, South Sudan, MSF treats around 300 snakebite patients per year.Most of them during the rainy season. Many people get bitten inside their houses, as the snakes go there in search of dry areas. Snakebite mainly affects children and people working in the fields. Few villages are spared and everyone has the same problem – getting treatment.
29/03/2019

Mapping the needs: new technologies help the emergency response

As well as providing healthcare to people affected by the cyclone and flooding disaster, MSF deployed four GIS (Geographic Information Systems) experts to provide maps to help the humanitarian response. 

Neglected Diseases 

Neglected diseases often affect people living in developing countries. As a result, pharmaceutical companies have little interest in working to find a cure for these diseases.  Stimulating awareness about the urgent need for new, better treatment and tests for diseases like leishmaniasis, sleeping sickness and Chagas  disease  is key to the work of MSF’s Access Campaign and the Drugs for Neglected Diseases Initiative (DNDi) of which MSF was a founding partner.